{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:50:51Z","timestamp":1791975051633,"version":"4.4.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Shenzhen Yantian District Science and Technology Bureau","award":["YTWS20240108"],"award-info":[{"award-number":["YTWS20240108"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Science Progress"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the effects of early evolocumab plus atorvastatin on lipid metabolism, circulating endothelial biomarkers, and inflammation in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center, open-label trial, 90 patients were randomized 1:1 to atorvastatin 20 mg\/day (control, n=45) or atorvastatin 20 mg\/day plus evolocumab 140 mg biweekly (combination, n=45) for 12 weeks. One patient withdrew from the combination group at day 28; last-observation-carried-forward (LOCF) was applied to impute missing 12-week endpoints for the withdrawn participant. All 90 randomized patients were included in the intention-to-treat (ITT) analytic population. Lipid profiles, endothelial biomarkers, inflammatory cytokines, and safety outcomes were assessed at baseline and 12 weeks. Standard Analysis of Covariance (ANCOVA) with 12-week value as dependent variable and corresponding baseline level as covariate was used to compare between-group treatment effects for normally distributed outcomes; non-parametric tests were applied for non-normally distributed data. All secondary biomarker, cardiac function and safety analyses were predefined as exploratory without multiplicity adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline characteristics were well-balanced. The primary endpoint\u2014change in LDL-C from baseline\u2014was significantly greater in the combination group (adjusted mean difference: -0.31 mmol\/L, 95% CI: -0.60 to -0.02, P=0.037). A significantly higher proportion achieved the guideline-recommended LDL-C target of &lt;1.4 mmol\/L (48.89% vs. 22.2%, P=0.007). Secondary endpoints showed favorable changes in nitric oxide, endothelin-1, and sICAM-1 (all P&lt;0.05), and a significant reduction in IL-6 by non-parametric testing (P=0.005). No significant between-group differences were observed for other biomarkers, cardiac function indices, or adverse events (all P&gt;0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this small, single-center trial, early evolocumab added to moderate-intensity atorvastatin was associated with additional LDL-C reduction and favorable changes in selected circulating endothelial biomarkers and IL-6 over 12 weeks in STEMI patients post-PPCI, no major safety signal was observed in this short-term study. These findings are preliminary and require confirmation in larger, adequately powered trials using guideline-directed high-intensity statin therapy as the standard of care. Chinese Clinical Trial Register submission ID: PID343553 (application currently under administrative review, not publicly released).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00368504261495912","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:14:51Z","timestamp":1791634491000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of evolocumab on lipid profile and circulating endothelial biomarkers in patients undergoing primary percutaneous coronary intervention"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-034X","authenticated-orcid":false,"given":"Wenlong","family":"Jiang","sequence":"first","affiliation":[{"name":"Shenzhen Yantian district people\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[{"name":"Shenzhen Yantian district people\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuang","family":"Xiong","sequence":"additional","affiliation":[{"name":"Shenzhen Yantian district people\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Shenzhen Yantian district people\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzhou","family":"Cheng","sequence":"additional","affiliation":[{"name":"Shenzhen Yantian district people\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12113-7"},{"issue":"12","key":"e_1_3_6_5_2","first-page":"1454","article-title":"Myocardial reperfusion injury: a neglected therapeutic target","volume":"72","author":"Hausenloy DJ","year":"2018","unstructured":"Hausenloy DJ, Yellon DM. Myocardial reperfusion injury: a neglected therapeutic target. J Am Coll Cardiol 2018; 72(12): 1454\u20131468. https:\/\/doi.org\/10.1016\/j.jacc.2018.07.047","journal-title":"J Am Coll Cardiol"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"issue":"12","key":"e_1_3_6_7_2","first-page":"1762","article-title":"Progress in atherosclerosis: from lipid accumulation to inflammation and beyond","volume":"124","author":"Libby P","year":"2019","unstructured":"Libby P, Hansson GK, Ridker PM. Progress in atherosclerosis: from lipid accumulation to inflammation and beyond. Circ Res 2019; 124(12): 1762\u20131776. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.314465","journal-title":"Circ Res"},{"issue":"1","key":"e_1_3_6_8_2","first-page":"362","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"44","author":"Mach F","year":"2023","unstructured":"Mach F, Baigent C, Catapano AL, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2023; 44(1): 362\u2013446. https:\/\/doi.org\/10.1093\/eurheartj\/ehab771","journal-title":"Eur Heart J"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003"},{"issue":"2","key":"e_1_3_6_10_2","first-page":"e82","article-title":"Statin-associated muscle symptoms: impact, mechanisms, and management: a scientific statement from the American Heart Association","volume":"137","author":"Rosenson RS","year":"2018","unstructured":"Rosenson RS, Reiner Z, Catapano AL, et al. Statin-associated muscle symptoms: impact, mechanisms, and management: a scientific statement from the American Heart Association. Circulation 2018; 137(2): e82\u2013e110. https:\/\/doi.org\/10.1161\/CIR.0000000000000523","journal-title":"Circulation"},{"issue":"39","key":"e_1_3_6_11_2","first-page":"3630","article-title":"PCSK9 inhibitors: an update from the European Atherosclerosis Society","volume":"41","author":"Raal FJ","year":"2020","unstructured":"Raal FJ, Catapano AL, Desai NR, et al. PCSK9 inhibitors: an update from the European Atherosclerosis Society. Eur Heart J 2020; 41(39): 3630\u20133643. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa507","journal-title":"Eur Heart J"},{"issue":"5","key":"e_1_3_6_12_2","first-page":"275","article-title":"PCSK9 inhibitors: clinical evidence and future perspectives","volume":"15","author":"Khera AV","year":"2018","unstructured":"Khera AV, Stroes ES, Mach F, et al. PCSK9 inhibitors: clinical evidence and future perspectives. Nat Rev Cardiol 2018; 15(5): 275\u2013289. https:\/\/doi.org\/10.1038\/nrcardio.2018.22","journal-title":"Nat Rev Cardiol"},{"issue":"10172","key":"e_1_3_6_13_2","first-page":"707","article-title":"PCSK9 inhibition: a new frontier in cardiovascular disease treatment","volume":"393","author":"Cohen J","year":"2019","unstructured":"Cohen J, Khera AV, Mach F. PCSK9 inhibition: a new frontier in cardiovascular disease treatment. Lancet 2019; 393(10172): 707\u2013718. https:\/\/doi.org\/10.1016\/S0140-6736(18)32205-6","journal-title":"Lancet"},{"issue":"8","key":"e_1_3_6_14_2","first-page":"1567","article-title":"PCSK9 inhibition improves endothelial function via LDL-C-independent mechanisms in atherosclerosis","volume":"39","author":"Tang WH","year":"2019","unstructured":"Tang WH, Sato Y, Kitai T, et al. PCSK9 inhibition improves endothelial function via LDL-C-independent mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2019; 39(8): 1567\u20131579. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312781","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"e_1_3_6_15_2","first-page":"102","article-title":"PCSK9 silencing attenuates vascular inflammation and atherosclerosis in apolipoprotein E-deficient mice","volume":"301","author":"Ishibashi S","year":"2020","unstructured":"Ishibashi S, Shimada K, Sakai N, et al. PCSK9 silencing attenuates vascular inflammation and atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2020; 301: 102\u2013110. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.03.016","journal-title":"Atherosclerosis"},{"key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell S","year":"2025","unstructured":"Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ 2025; 389: e081123. https:\/\/doi.org\/10.1136\/bmj-2024-081123","journal-title":"BMJ"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.08.488"},{"issue":"3","key":"e_1_3_6_18_2","first-page":"70","article-title":"Safety and efficacy of high-potency statin in Chinese patients with established cardiovascular disease","volume":"30","author":"Tang HY","year":"2023","unstructured":"Tang HY, Lau KC, Yan BP, et al. Safety and efficacy of high-potency statin in Chinese patients with established cardiovascular disease. HKPharm J 2023; 30(3): 70.","journal-title":"HKPharm J"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn416"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"e_1_3_6_22_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf Published November 27 2017."},{"issue":"20","key":"e_1_3_6_23_2","first-page":"1897","article-title":"Evolocumab in high-risk patients without prior myocardial infarction or stroke","volume":"393","author":"Sabatine MS","year":"2025","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Evolocumab in high-risk patients without prior myocardial infarction or stroke. N Engl J Med 2025; 393(20): 1897\u20131907. https:\/\/doi.org\/10.1056\/NEJMoa2500488","journal-title":"N Engl J Med"},{"issue":"10","key":"e_1_3_6_24_2","first-page":"994","article-title":"PCSK9 inhibitors in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis","volume":"78","author":"Toth PP","year":"2021","unstructured":"Toth PP, Bittencourt MS, Jones PH, et al. PCSK9 inhibitors in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis. J Am Coll Cardiol 2021; 78(10): 994\u20131004. https:\/\/doi.org\/10.1016\/j.jacc.2021.06.045","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"e_1_3_6_25_2","first-page":"169","article-title":"Endothelial function and dysfunction: testing and clinical relevance in cardiovascular disease","volume":"38","author":"Deanfield JE","year":"2017","unstructured":"Deanfield JE, Halcox JP, Chin-Dusting JP, et al. Endothelial function and dysfunction: testing and clinical relevance in cardiovascular disease. Eur Heart J 2017; 38(3): 169\u2013176. https:\/\/doi.org\/10.1093\/eurheartj\/ehw210","journal-title":"Eur Heart J"},{"issue":"1","key":"e_1_3_6_26_2","first-page":"136","article-title":"Nitric oxide in cardiovascular disease: from pathogenesis to therapy","volume":"128","author":"Munzel T","year":"2021","unstructured":"Munzel T, Gori T, Vallance P. Nitric oxide in cardiovascular disease: from pathogenesis to therapy. Circ Res 2021; 128(1): 136\u2013156. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.316426","journal-title":"Circ Res"},{"issue":"3","key":"e_1_3_6_27_2","first-page":"411","article-title":"Endothelin system: from discovery to clinical application","volume":"70","author":"Yanagisawa M","year":"2018","unstructured":"Yanagisawa M, Masaki T. Endothelin system: from discovery to clinical application. Pharmacol Rev 2018; 70(3): 411\u2013450. https:\/\/doi.org\/10.1124\/pr.117.014498","journal-title":"Pharmacol Rev"},{"issue":"2","key":"e_1_3_6_28_2","first-page":"103","article-title":"Adhesion molecules in inflammation and immune disorders","volume":"18","author":"Springer TA","year":"2018","unstructured":"Springer TA. Adhesion molecules in inflammation and immune disorders. Nat Rev Immunol 2018; 18(2): 103\u2013118. https:\/\/doi.org\/10.1038\/nri.2017.120","journal-title":"Nat Rev Immunol"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12030578"},{"issue":"12","key":"e_1_3_6_30_2","first-page":"3271","article-title":"Long-term effects of evolocumab on lipid profile and inflammatory biomarkers: a sex-based analysis","volume":"11","author":"Ciocci M","year":"2023","unstructured":"Ciocci M, Di Pino A, Urbano F, et al. Long-term effects of evolocumab on lipid profile and inflammatory biomarkers: a sex-based analysis. Biomedicines 2023; 11(12): 3271. https:\/\/doi.org\/10.3390\/biomedicines11123271","journal-title":"Biomedicines"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.11.011"},{"issue":"1","key":"e_1_3_6_32_2","first-page":"115","article-title":"Inflammation and coagulation in acute myocardial infarction","volume":"121","author":"van der Poll T","year":"2017","unstructured":"van der Poll T, Levi M. Inflammation and coagulation in acute myocardial infarction. Circ Res 2017; 121(1): 115\u2013129. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310132","journal-title":"Circ Res"},{"issue":"12","key":"e_1_3_6_33_2","first-page":"5664","article-title":"Evolocumab alleviates myocardial ischemia-reperfusion injury by inhibiting NLRP3 inflammasome activation","volume":"25","author":"Zhang L","year":"2021","unstructured":"Zhang L, Li Y, Wang H, et al. Evolocumab alleviates myocardial ischemia-reperfusion injury by inhibiting NLRP3 inflammasome activation. J Cell Mol Med 2021; 25(12): 5664\u20135675. https:\/\/doi.org\/10.1111\/jcmm.16573","journal-title":"J Cell Mol Med"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"issue":"12","key":"e_1_3_6_35_2","first-page":"1423","article-title":"Early evolocumab after acute coronary syndrome and long-term outcomes","volume":"41","author":"Giugliano RP","year":"2020","unstructured":"Giugliano RP, Sabatine MS, Wiviott SD, et al. Early evolocumab after acute coronary syndrome and long-term outcomes. Eur Heart J 2020; 41(12): 1423\u20131431. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa030","journal-title":"Eur Heart J"},{"issue":"37","key":"e_1_3_6_36_2","first-page":"3599","article-title":"2022 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"43","author":"Ponikowski P","year":"2022","unstructured":"Ponikowski P, Vaduganathan M, Anker SD, et al. 2022 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2022; 43(37): 3599\u20133678. https:\/\/doi.org\/10.1093\/eurheartj\/ehac004","journal-title":"Eur Heart J"},{"issue":"39","key":"e_1_3_6_37_2","first-page":"3753","article-title":"5-year safety and efficacy of evolocumab in patients with cardiovascular disease","volume":"41","author":"Sabatine MS","year":"2020","unstructured":"Sabatine MS, Everett BM, Rawlings C, et al. 5-year safety and efficacy of evolocumab in patients with cardiovascular disease. Eur Heart J 2020; 41(39): 3753\u20133762. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa671","journal-title":"Eur Heart J"}],"container-title":["Science Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261495912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00368504261495912","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261495912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:16:13Z","timestamp":1791972973000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00368504261495912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/00368504261495912"],"URL":"https:\/\/doi.org\/10.1177\/00368504261495912","relation":{},"ISSN":["0036-8504","2047-7163"],"issn-type":[{"value":"0036-8504","type":"print"},{"value":"2047-7163","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"article-number":"00368504261495912"}}